Type 2 Diabetes Mellitus
Conditions
Brief summary
This is a prospective, interventional, single arm, multicenter, phase 4 study to evaluate the clinical efficacy and safety of initiating Insulin glargine U300 in insulin-naive patients or switching from any other basal insulin to Insulin glargine U300 in insulin pre-treated patients with uncontrolled T2DM.
Detailed description
Maximum study duration per participant will be approximately 37 weeks per patient: up to 1 week screening period, 24 weeks insulin glargine U300 treatment period and 12 weeks observational extension period.
Interventions
Solution for injection Subcutaneous injection
Sponsors
Sanofi
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients (age≥18 years) who diagnosed with type 2 diabetes * Patients who should initiate Insulin glargine U300 treatment following local label and guideline at investigator's discretion, including: * insulin naive patients (no current or previous insulin used during the last year prior to screening except for a maximum 10 days in relation to acute illness or surgery, etc.) uncontrolled (HbA1c between 7.5% and 11.0%) at screening visit on stable dose treatment with ≤ 2 OADs (metformin, sulfonylurea, thiazolidinedione, DPP-4 inhibitor, SGLT-2 inhibitor, glinide, α-glucosidase inhibitor) within 8 weeks prior to screening, at least one of which must be on maximum tolerated dose, or * patients uncontrolled (HbA1c between 7.5% and 11.0%) at screening visit with other basal insulin, or * patients controlled with other basal insulin but experienced frequent hypoglycemia or with increased hypoglycemia risk at investigator's discretion * Patients who treated with basal insulin must have a stable dose of antidiabetic drugs (dose change no more than ±20% vs. the dose on screening visit for basal insulin) within 8 weeks prior to screening
Exclusion criteria
* Any clinically significant abnormality identified on physical examination, laboratory tests, or vital signs at the time of screening, or at baseline, or any major systemic disease resulting in short life expectancy that in the opinion of the Investigator would restrict or limit the patient's successful participation for the duration of the study * Use of any product containing short or rapid acting insulin in the last 3 months prior to screening (unless used for ≤10 days in relation to hospitalization or an acute illness) * Use of oral anti-diabetic drugs other than those allowed and listed in the inclusion criteria, Glucagon-like peptide-1 (GLP-1) receptor agonists, or any investigational agent (drug, biologic, device) within 3 months prior to screening visit * Use of systemic glucocorticoids (excluding topical application or inhaled forms) for two weeks or more within 8 weeks prior to the time of screening * Known hypersensitivity / intolerance to insulin glargine or any of its excipients * Pregnant or lactating women * Women of childbearing potential with no effective contraceptive method * Participation in another clinical trial The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change in HbA1c from baseline to week 24 | Baseline to Week 24 |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of participants achieving HbA1c target <7% | at Week 12, 24 and 36 |
| Percentage of participants achieving HbA1c target <7% without hypoglycemic events | at Week 12 and 24 |
| Mean change in Fasting Plasma Glucose (FPG) from baseline to week 12, 24 and 36 | Baseline to Week 12, 24 and 36 |
| Mean change in fasting Self-Monitored Blood Glucose (SMBG) from baseline to week 12 and week 24 | Baseline to Week 12 and 24 |
| Mean change in of 7-points SMBG per time point from baseline to week 12 and week 24 | Baseline to Week 12 and 24 |
| Mean change in HbA1c from baseline to week 12 and week 36 | Baseline to Week 12 and 36 |
| Number of participants experiencing hypoglycemia from baseline to week 12, 24 and 36 | Baseline to Week 12, 24 and 36 |
| Number of hypoglycemic events per patient-year | Baseline to Week 12, 24 and 36 |
| Number of participants with adverse events | Baseline to Week 24 and 36 |
| Mean change in body weight from baseline to Week 12 and Week 24 | Baseline to Week 12 and 24 |
| Mean change in Insulin glargine U300 dose from baseline to week 12, 24 and 36 | Baseline to Week 12, 24 and 36 |
Countries
China
Outcome results
None listed